Bruce Cozadd Sells 77,500 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 77,500 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the sale, the director directly owned 393,332 shares of the company’s stock, valued at $69,938,362.92. The trade was a 16.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ:JAZZ traded down $4.41 during mid-day trading on Monday, hitting $172.12. 1,524,563 shares of the company traded hands, compared to its average volume of 952,753. The firm’s 50 day simple moving average is $144.71 and its 200 day simple moving average is $125.74. The firm has a market cap of $10.46 billion, a P/E ratio of -25.57, a PEG ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research note on Monday, November 17th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Finally, Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $195.67.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 81 shares during the period. Tectonic Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after purchasing an additional 82 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Jazz Pharmaceuticals by 0.6% during the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after purchasing an additional 90 shares during the period. Fairbanks Capital Management Inc. grew its position in Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 94 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its position in Jazz Pharmaceuticals by 8.7% during the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock valued at $133,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.